Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Amps Up "Name And Shame" Approach To Thwart Anti-Generic Tactics

Executive Summary

New draft guidance says citizen petition abuses will be referred to FTC and publicly called out as attempts to delay ANDA approvals.
Advertisement

Related Content

FTC 'Ready' To Go After Abusive Citizen Petitions; Allergan Wants 'Substantive' FDA Responses
FTC 'Ready' To Go After Abusive Citizen Petitions; Allergan Wants 'Substantive' FDA Responses
Real-World Evidence Could Speed Development Of Drugs Offering Incremental Improvements
Credibility And Crying Wolf: US FDA Petition Guidance Says Past Practices Can Count Against You
Credibility And Crying Wolf: US FDA Petition Guidance Says Past Practices Can Count Against You
Will CBO Score CREATE Momentum For Generic Bill's Passage?
REMS Abuse Website: All Sizzle, No Steak?
FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting
Citizen Petitions Targeting ANDAs Recede, But Concerns Over Resources Remain

Topics

Advertisement
UsernamePublicRestriction

Register

PS123989

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel